Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

Neurological complication may result from rapid withdrawal from pregabalin

A report in the July Annals of Neurology describes a serious adverse event experienced by a participant in a clinical trial that may raise a new caution about the use of antiepileptic drugs for conditions other than epilepsy.

6 Jul 2005

Canada first country to approve cannabis based painkiller

Canada has become the first country to approve a cannabis based painkiller for multiple sclerosis (MS) patients.

21 Jun 2005

Venom of marine cone snails may provide an improved treatment for neuropathic pain associated with diabetes

A cone snail toxin discovered by Melbourne researchers has proven to have great potential for easing pain and could provide an improved treatment for neuropathic pain associated with diabetes.

12 Jun 2005

Scientists develop a way to block the signals responsible for neuropathic pain

Remember how it felt the last time you burned your finger on a hot stove? Imagine what it's like to have that burning pain in your hands or feet all the time and know there's virtually nothing you can do about it.

1 Jun 2005

Narcotic medications can safely and effectively ease severe, chronic pain in older people

Narcotic medications can safely and effectively ease severe, chronic pain in older people with little risk that these patients will seek ever-increasing doses, UCSF medical scientists have found. Younger patients, however, are likely to want to rapidly increase their medication dose, the researchers found, posing serious potential health consequences.

23 May 2005

Narcotic medications can safely and effectively ease severe, chronic pain in older people

Narcotic medications can safely and effectively ease severe, chronic pain in older people with little risk that these patients will seek ever-increasing doses, University of California, San Francisco (UCSF) medical scientists have found. Younger patients, however, are likely to want to rapidly increase their medication dose, the researchers found, posing serious potential health consequences.

20 May 2005

Drug that reduces the pain of fibromyalgia and improves sleep

A study of a drug that reduces the pain of fibromyalgia and improves sleep is published by a University of Kentucky physician in the peer-reviewed journal, Arthritis & Rheumatism.

12 Apr 2005

Chronic pain treatments more effective when taken together

People suffering from chronic, debilitating pain caused by nerve damage or disease report better pain relief at lower doses of a combined drug treatment than from either drug administered individually, a new Queen’s study funded by the Canadian Institutes of Health Research (CIHR) shows.

3 Apr 2005

Neuren and Metabolic collaborate to develop range of nerve repair compounds

Neuren Pharmaceuticals Ltd (Neuren) and Metabolic Pharmaceuticals Ltd (Metabolic) have announced that the two companies have agreed to collaborate to co-develop Neuren's class of Neuro-regenerative Peptides (NRPs) for the treatment of degenerative conditions such as peripheral neuropathy, motor neuron disease and repairing the brain or nerves after injuries such as spinal cord injury.

7 Mar 2005

Marijuana-like compounds may aid Parkinson's disease, pain and obesity

No longer a pipe dream, new animal research now indicates that marijuana-like compounds can aid a bevy of debilitating conditions, ranging from brain disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, to pain and obesity.

28 Oct 2004

Cymbalta significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression

The antidepressant Cymbalta (duloxetine HCl), a dual-reuptake inhibitor of serotonin and norepinephrine, 60 mg once or twice daily, significantly reduced pain in more than half of women treated for fibromyalgia, with and without major depression, according to 12-week data presented at the annual meeting of the American College of Rheumatology.

18 Oct 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Botox injections may ease the irritation of tinnitus

A preliminary study indicates that Botox injections may ease the irritation of tinnitus, otherwise know as ringing in the ears, for some patients. Researchers say more study is needed, but initial results are promising.

18 Sep 2004

Cymbalta, treatment for major depression hits the market

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company has announced.

26 Aug 2004

Cymbalta, a new treatment for major depression

Cymbalta, a new treatment for major depression, is now available by prescription in pharmacies across the United States, Eli Lilly and Company have announced.

25 Aug 2004

Sea snail offers natural healing powers for a range of illnesses from chronic pain to diseases of the brain

A beautiful, but often deadly, snail from the sea has been revealed as a largely untapped source of natural healing powers for a range of illnesses from chronic pain to diseases of the brain.

20 Aug 2004

New biotech alliance to focus on diseases of nerve injury and pain

NeuroTargets Ltd, a discovery-led biotechnology company ‘spun-out’ from the University of Bristol, has formed an exciting new alliance with BioFocus plc, a world leader in collaborative drug discovery, to focus on diseases of nerve injury and pain.

11 Aug 2004

Approval of Cymbalta for treatment of major depressive disorder

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl; pronounced SIM-BALL-TA), judging it a safe and effective treatment for major depressive disorder, Eli Lilly and Company have announced.

5 Aug 2004

Cannabis extract drug may help patients with rheumatoid arthritis

The multi centre double blind, randomised, parallel group study in 58 patients assessed the efficacy, safety and tolerability of Sativex®, a whole plant medicinal cannabis extract, compared with placebo for the treatment of pain caused by Rheumatoid Arthritis. Study medication was administered by means of a spray into the mouth as an evening dose only and measures were assessed the following day.

11 Jun 2004

A new synthetic chemical may provide framework for future drugs to treat brain-based ailments

A new synthetic chemical may provide the framework for future drugs that can treat a variety of brain-based ailments, ranging from overeating and drug dependency to neuropathic pain.

19 May 2004